☆ 4.7 Article

Design, synthesis, and metabolite identification of Tamoxifen esterase-activatable

BIOORGANIC CHEMISTRY (2023)

Related references

Note: Only part of the references are listed.

Article Obstetrics & Gynecology

Gynecological management of the breast cancer survivor

Mary Kathryn et al.

Summary: Survival rates of breast cancer patients have been increasing since the 1990s, highlighting the importance of addressing quality of life and gynecologic concerns. Breast cancer diagnosis and treatment uniquely impact women's health issues such as contraception, pregnancy, menopause, and sexual functioning. Hormone-sensitive breast cancer accounts for two-thirds of cases, and adjuvant hormonal therapies have significantly reduced disease recurrence and contralateral breast cancer risk. However, these therapies can lead to menopausal and sexual side effects, requiring healthcare providers to be knowledgeable about safe and effective treatment options.

BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY (2022)

Add to Collection

Article Oncology

CYP2D6 genotype predicts tamoxifen discontinuation and drug response: a secondary analysis of the KARISMA trial

W. He et al.

Summary: This study found that poor CYP2D6 metabolizers are more likely to experience an impaired response to tamoxifen, while ultrarapid metabolizers are at risk for exaggerated response and may lead to treatment discontinuation.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Toxicology

Human Variability in Carboxylesterases and carboxylesterase-related Uncertainty Factors for Chemical Risk Assessment

E. Di Consiglio et al.

Summary: Carboxylesterases are important enzymes with large inter-individual variability, with most healthy adults covered by the kinetic default UF except for certain drugs like clopidogrel and dabigatran etexilate. Variability in drug metabolism and absorption may contribute to CES-related variability in vivo.

TOXICOLOGY LETTERS (2021)

Add to Collection

Review Oncology

Clinical CYP2D6 Genotyping to Personalize Adjuvant Tamoxifen Treatment in ER-Positive Breast Cancer Patients: Current Status of a Controversy

Tessa A. M. Mulder et al.

Summary: Tamoxifen is a crucial adjuvant endocrine therapy for estrogen receptor (ER)-positive breast cancer patients, with the conversion to the active metabolite endoxifen mainly depending on the CYP2D6 enzyme. Genetic variations in the CYP2D6 gene can impact endoxifen formation and therapy outcomes, though the correlation between CYP2D6 genotype and clinical outcome remains debated. Recent developments from 2018 to 2020 shed light on this ongoing debate.

CANCERS (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Metabolic reprograming confers tamoxifen resistance in breast cancer

Alok Mishra et al.

Summary: Breast cancer is the most common cancer among females, and endocrine therapy for ER-positive breast cancer can result in acquired resistance. The metabolic state of cancer cells plays a crucial role in their susceptibility to chemotherapeutic drugs, and understanding metabolic pathway alterations in TAMR cancer may offer potential therapeutic strategies.

CHEMICO-BIOLOGICAL INTERACTIONS (2021)

Add to Collection

Review Oncology

Tamoxifen and oxidative stress: an overlooked connection

Nermin S. Ahmed et al.

Summary: Tamoxifen is the gold standard drug for treating breast cancer, initially believed to work through estrogen receptor mechanism but later proven to act through multiple non-estrogen receptor mechanisms. Additionally, the connection between tamoxifen's apoptotic effects and oxidative stress is often overlooked.

DISCOVER ONCOLOGY (2021)

Add to Collection

Review Oncology

Tamoxifen and Endometrial Cancer: A Janus-Headed Drug

Gunter Emons et al.

CANCERS (2020)

Add to Collection

Letter Oncology

Tamoxifen Pharmacogenetics and Metabolism: The Same Is Not the Same

Hiltrud Brauch et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Review Pharmacology & Pharmacy

Human carboxylesterases: a comprehensive review

Dandan Wang et al.

ACTA PHARMACEUTICA SINICA B (2018)

Add to Collection

Article Microbiology

Repurposing Estrogen Receptor Antagonists for the Treatment of Infectious Disease

Marhiah C. Montoya et al.

MBIO (2018)

Add to Collection

Review Biochemistry & Molecular Biology

Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis

Yixiao Feng et al.

GENES & DISEASES (2018)

Add to Collection

Article Pharmacology & Pharmacy

Tamoxifen from Failed Contraceptive Pill to Best-Selling Breast Cancer Medicine: A Case-Study in Pharmaceutical Innovation

Viviane M. Quirke

FRONTIERS IN PHARMACOLOGY (2017)

Add to Collection

Review Pharmacology & Pharmacy

Challenges and Opportunities with Non-CYP Enzymes Aldehyde Oxidase, Carboxylesterase, and UDP-Glucuronosyltransferase: Focus on Reaction Phenotyping and Prediction of Human Clearance

Upendra A. Argikar et al.

AAPS JOURNAL (2016)

Add to Collection

Article Pharmacology & Pharmacy

Association of Oseltamivir Activation with Gender and Carboxylesterase 1 Genetic Polymorphisms

Jian Shi et al.

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2016)

Add to Collection

Article Chemistry, Medicinal

Design and synthesis of novel flexible ester-containing analogs of tamoxifen and their evaluation as anticancer agents

Nehal H. Elghazawy et al.

FUTURE MEDICINAL CHEMISTRY (2016)

Add to Collection

Article Chemistry, Medicinal

Design, synthesis and biological evaluation of novel triaryl (Z)-olefins as tamoxifen analogues

Khaled R. A. Abdellatif et al.

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)

Add to Collection

Article Food Science & Technology

p-Hydroxybenzoate esters metabolism in MCF7 breast cancer cells

Zeina Dagher et al.

FOOD AND CHEMICAL TOXICOLOGY (2012)

Add to Collection

Article Oncology

The NCI60 human tumour cell line anticancer drug screen

Robert H. Shoemaker

NATURE REVIEWS CANCER (2006)

Add to Collection

Article Chemistry, Medicinal

Antiestrogenically Active 2-benzyl-1,1-diarylbut-2-enes: Synthesis, Structure-Activity Relationships and Molecular Modeling Study for Flexible Estrogen Receptor Antagonists

David G. Lloyd et al.

MEDICINAL CHEMISTRY (2006)

Add to Collection

Article Chemistry, Medicinal

Synthesis, Structure-Activity Relationships and Antagonistic Effects in Human MCF-7 Breast Cancer Cells of Flexible Estrogen Receptor Modulators

David G. Lloyd et al.

MEDICINAL CHEMISTRY (2005)

Add to Collection

© Peeref 2019-2024. All rights reserved.